RDHL (Redhill Biopharma Ltd.) Stock Analysis - AI Report

Redhill Biopharma Ltd. (RDHL) is a publicly traded Healthcare sector company. As of May 21, 2026, RDHL trades at $0.92 with a market cap of $4.85M and a P/E ratio of 0.00. RDHL moved -0.98% today. Year to date, RDHL is -34.36%; over the trailing twelve months it is -51.63%. Its 52-week range spans $0.71 to $9.25. Rallies surfaces RDHL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on RDHL?

Rallies AI research for RDHL combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

RDHL Key Metrics

Key financial metrics for RDHL
MetricValue
Price$0.92
Market Cap$4.85M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$9.25
52-Week Low$0.71
Volume0
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Latest RDHL News

Recent RDHL Insider Trades

  • Raday Gilead sold 15.74M (~$1.57K) on Apr 6, 2026.

RDHL Analyst Consensus

RDHL analyst coverage data. Average price target: $0.00.

Common questions about RDHL

What is the AI research view on RDHL?
Rallies AI research for RDHL combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for RDHL?
Rallies AI research for RDHL combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is RDHL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RDHL. It does not provide personalized investment advice.
RDHL

RDHL